Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells.

Warth B, Palermo A, Rattray NJW, Lee NV, Zhu Z, Hoang LT, Cai Y, Mazurek A, Dann S, VanArsdale T, Fantin VR, Shields D, Siuzdak G, Johnson CH.

Metabolites. 2019 Jan 2;9(1). pii: E7. doi: 10.3390/metabo9010007.

2.

Prospects in the Application of Photodynamic Therapy in Oral Cancer and Premalignant Lesions.

Saini R, Lee NV, Liu KY, Poh CF.

Cancers (Basel). 2016 Sep 2;8(9). pii: E83. doi: 10.3390/cancers8090083. Review.

3.

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.

Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW.

Mol Cancer Ther. 2016 Oct;15(10):2273-2281. Epub 2016 Aug 5.

4.

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP.

Cancer Discov. 2016 Jan;6(1):96-107. doi: 10.1158/2159-8290.CD-15-1056. Epub 2015 Nov 10.

5.

[11C]PBR28 PET imaging is sensitive to neuroinflammation in the aged rat.

Walker MD, Dinelle K, Kornelsen R, Lee NV, Miao Q, Adam M, Takhar C, Mak E, Schulzer M, Farrer MJ, Sossi V.

J Cereb Blood Flow Metab. 2015 Aug;35(8):1331-8. doi: 10.1038/jcbfm.2015.54. Epub 2015 Apr 1.

6.

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.

Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES.

Sci Signal. 2014 Nov 11;7(351):ra107. doi: 10.1126/scisignal.2005516.

PMID:
25389372
7.

Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).

Pavlicek A, Lira ME, Lee NV, Ching KA, Ye J, Cao J, Garza SJ, Hook KE, Ozeck M, Shi ST, Yuan J, Zheng X, Rejto PA, Kan JL, Christensen JG.

Mol Cancer Ther. 2013 Dec;12(12):2929-39. doi: 10.1158/1535-7163.MCT-13-0442-T. Epub 2013 Oct 9.

8.

Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer.

Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG.

Front Pharmacol. 2013 Mar 22;4:22. doi: 10.3389/fphar.2013.00022. eCollection 2013.

9.

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

Huang D, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M.

Genomics. 2013 Sep;102(3):157-62. doi: 10.1016/j.ygeno.2013.02.006. Epub 2013 Feb 20.

10.

Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.

Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, Zong Q, Lappin PB, Wong A, Rejto PA, Smeal T, Christensen JG.

Clin Cancer Res. 2012 Sep 15;18(18):5008-19. doi: 10.1158/1078-0432.CCR-12-1379. Epub 2012 Jul 17.

11.

A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.

Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S, Srinivasa SP, Zhao Y, Aparicio S, Rejto PA, Christensen JG, Ching KA.

PLoS One. 2012;7(6):e39653. doi: 10.1371/journal.pone.0039653. Epub 2012 Jun 22. Erratum in: PLoS One. 2012;7(8). doi: 10.1371/annotation/d988dd75-bcd2-4859-b20b-487e1bf2513b.

12.

An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, Yuan J, Ye J, Ozeck M, Shi ST, Zheng X, Rejto PA, Kan JL, Christensen JG, Pavlicek A.

Mol Cancer Ther. 2012 Mar;11(3):710-9. doi: 10.1158/1535-7163.MCT-11-0184. Epub 2012 Jan 5.

13.

Fibulin-1 is required during cardiac ventricular morphogenesis for versican cleavage, suppression of ErbB2 and Erk1/2 activation, and to attenuate trabecular cardiomyocyte proliferation.

Cooley MA, Fresco VM, Dorlon ME, Twal WO, Lee NV, Barth JL, Kern CB, Iruela-Arispe ML, Argraves WS.

Dev Dyn. 2012 Feb;241(2):303-14. doi: 10.1002/dvdy.23716. Epub 2011 Dec 19.

14.

Discovery of a novel B-Raf fusion protein related to c-Met drug resistance.

Dillon R, Nilsson CL, Shi SD, Lee NV, Krastins B, Greig MJ.

J Proteome Res. 2011 Nov 4;10(11):5084-94. doi: 10.1021/pr200498v. Epub 2011 Oct 12.

PMID:
21936566
15.

The relationship between exercise intensity and the sweat lactate excretion rate.

Buono MJ, Lee NV, Miller PW.

J Physiol Sci. 2010 Mar;60(2):103-7. doi: 10.1007/s12576-009-0073-3. Epub 2009 Dec 16.

PMID:
20013328
16.

The effect of spironolactone on sweat and urinary sodium excretion during exercise in humans.

Lee NV, Miller PW, Buono MJ.

Clin Physiol Funct Imaging. 2010 Jan;30(1):13-6. doi: 10.1111/j.1475-097X.2009.00898.x. Epub 2009 Sep 3.

PMID:
19732095
17.

Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis.

Stankunas K, Hang CT, Tsun ZY, Chen H, Lee NV, Wu JI, Shang C, Bayle JH, Shou W, Iruela-Arispe ML, Chang CP.

Dev Cell. 2008 Feb;14(2):298-311. doi: 10.1016/j.devcel.2007.11.018.

18.

ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2.

Lee NV, Sato M, Annis DS, Loo JA, Wu L, Mosher DF, Iruela-Arispe ML.

EMBO J. 2006 Nov 15;25(22):5270-83. Epub 2006 Nov 2.

19.

Fibulin-1 acts as a cofactor for the matrix metalloprotease ADAMTS-1.

Lee NV, Rodriguez-Manzaneque JC, Thai SN, Twal WO, Luque A, Lyons KM, Argraves WS, Iruela-Arispe ML.

J Biol Chem. 2005 Oct 14;280(41):34796-804. Epub 2005 Aug 1.

Supplemental Content

Support Center